more patients on the new anticoagulant dabigatran (Pradaxa) instead of warfarin for nonvalvular atrial fibrillation
January 2011
You'll see more patients on the new anticoagulant dabigatran (Pradaxa) instead of warfarin for nonvalvular atrial fibrillation.
It's not just because dabigatran doesn't need monitoring. Dabigatran also prevents more strokes than warfarin...about 5 more strokes per 1000 patients per year...with a similar OVERALL bleeding risk.
Some insurers now cover it WITHOUT a prior authorization...and Canadian guidelines already recommend it OVER warfarin for A fib.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote